The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Upadacitinib for RA

FDA Approves Upadacitinib for RA

September 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In August, the U.S. Food and Drug Administration (FDA) approved upadacitinib (Rinvoq) to treat adults with moderate to severe active rheumatoid arthritis (RA) who are methotrexate intolerant or for whom methotrexate was inadequate. The treatment is a once daily, oral Janus kinase (JAK) inhibitor and is approved in a 15 mg dose. This approval was based on data from the phase 3 SELECT program, which assessed more than 4,400 RA patients in five studies.1

You Might Also Like
  • Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector
  • Upadacitinib Meets Study Endpoints to Treat RA
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
Explore This Issue
October 2019
Also By This Author
  • Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

In the SELECT program, upadacitnib met all primary and ranked secondary endpoints. Additionally, upadacitinib-treated patients significantly inhibited radiographic progression, with or without methotrexate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Findings
In the SELECT-COMPARE trial, approximately 30% of upadacitinib-treated patients achieved clinical remission at Week 12, assessed by Disease Activity Score (DAS) 28 CRP score of less than 2.6, vs. 6% of placebo plus methotrexate-treated patients. By Week 14 of the SELECT-MONOTHERAPY trial only 8% of placebo plus methotrexate-treated patients achieved clinical remission. In SELECT-EARLY clinical trial, 52% of upadacitinib-treated patients who were methotrexate-naive achieved ACR50 at Week 12 compared with 28% of methotrexate-treated patients. Additionally at Week 12, 36% of upadacitinib-treated patients achieved clinical remission according to the DAS28-CRP vs. 14% of placebo plus methotrexate-treated patients.

Durable remission rates were seen up to Week 26. In the SELECT-EARLY trial, 48% of upadacitinib-treated monotherapy patients achieved clinical remission at Week 24 vs. 9% of placebo plus methotrexate-treated patients. Also 41% of upadacitinib plus methotrexate-treated patients in the SELECT-COMPARE trial achieved clinical remission at Week 26 compared with 18% of placebo plus methotrexate-treated patients. At Weeks 24 and 26, analyses were not controlled for multiple comparisons.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Inhibition of radiographic progression was measured by the change in modified total Sharp score (mTSS) from baseline compared with methotrexate through Week 24 in SELECT-EARLY and for upadacitinib plus MTX-treated patients compared with placebo plus MTX-treated patients in SELECT-COMPARE trial through Week 26. In the clinical trials, the most common side effects were cough, nausea, pyrexia and upper respiratory tract infection.

Upadacitinib is also being investigated to treat other immune-mediated diseases. The European Medicines Agency, as well as regulatory authorities in Canada and Japan, are evaluating upadacitinib for treating adults with moderate to severe active RA.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. AbbVie Inc. New releases: AbbVie receives FDA qpproval of Rinvoq (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis. 2019 Aug 16.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: FDA, FDA approval, Rheumatoid Arthritis (RA), U.S. Food and Drug Administration (FDA), upadacitinibIssue: October 2019

You Might Also Like:
  • Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector
  • Upadacitinib Meets Study Endpoints to Treat RA
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib at the FDA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)